Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines

Experimental Cell Research

Volumn 318, Issue 15, 2012, Pages 1832-1843

  Di Fazio, Pietro ^a   Montalbano, Roberta ^a   Neureiter, Daniel ^b   Alinger, Beate ^b   Schmidt, Ansgar ^a   Merkel, Anna Lena ^a   Quint, Karl ^a   Ocker, Matthias ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

HMGA2; Hsa let 7b; Liver cancer; Oncogenes; Pan deacetylase inhibitor

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; HSA LET 7B PROTEIN; MICRORNA; OLIGONUCLEOTIDE; PANOBINOSTAT; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANALYZER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL FATE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84863781353     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.04.018     Document Type: Article

References (62)

1. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., Horvitz H.R., Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in caenorhabditis elegans. Nature 2000, 403:901-906.
2. Macfarlane L.A., Murphy P.R. MicroRNA: biogenesis, function and role in cancer. Curr. Genomics 2010, 11:537-561.
3. Tan G.S., Garchow B.G., Liu X., Metzler D., Kiriakidou M. Clarifying mammalian RISC assembly in vitro, BMC. Mol. Biol. 2011, 12:19.
4. Ventura A., Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
5. Visone R., Croce C.M. MiRNAs and cancer. Am. J. Pathol. 2009, 174:1131-1138.
6. Ruan K., Fang X., Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009, 285:116-126.
7. Boyerinas B., Park S.M., Hau A., Murmann A.E., Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17:F19-36.
8. Liu Q., Lv G.D., Qin X., Gen Y.H., Zheng S.T., Liu T., Lu X.M. Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol. Biol. Rep. 2011.
9. Joynt S., Morillo V., Leng F. Binding the mammalian high mobility group protein AT-hook 2 to AT-rich deoxyoligonucleotides: enthalpy-entropy compensation. Biophys. J. 2009, 96:4144-4152.
10. Winter N., Nimzyk R., Bosche C., Meyer A., Bullerdiek J. Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PLoS One 2011, 6:e18837.
11. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
12. Palmieri D., Valentino T., D'Angelo D., De Martino I., Postiglione I., Pacelli R., Croce C.M., Fedele M., Fusco A. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene 2011, 30:3024-3035.
13. Li A.Y., Lin H.H., Kuo C.Y., Shih H.M., Wang C.C., Yen Y., Ann D.K. High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol. Cell. Biol. 2011, 31:2605-2617.
14. Ashar H.R., Fejzo M.S., Tkachenko A., Zhou X., Fletcher J.A., Weremowicz S., Morton C.C., Chada K. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995, 82:57-65.
15. Schoenmakers E.F., Wanschura S., Mols R., Bullerdiek J., Van den Berghe H., Van de Ven W.J. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat. Genet. 1995, 10:436-444.
16. Pierron A., Fernandez C., Saada E., Keslair F., Hery G., Zattara H., Pedeutour F. HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genet. Cytogenet. 2009, 195:66-70.
17. Klemke M., Meyer A., Nezhad M.H., Bartnitzke S., Drieschner N., Frantzen C., Schmidt E.H., Belge G., Bullerdiek J. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 2009, 48:171-178.
18. Kazmierczak B., Rosigkeit J., Wanschura S., Meyer-Bolte K., Van de Ven W.J., Kayser K., Krieghoff B., Kastendiek H., Bartnitzke S., Bullerdiek J. HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. Oncogene 1996, 12:515-521.
19. Staats B., Bonk U., Wanschura S., Hanisch P., Schoenmakers E.F., Van de Ven W.J., Bartnitzke S., Bullerdiek J. A fibroadenoma with a t(4;12) (q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein gene family. Breast Cancer Res. Treat. 1996, 38:299-303.
20. Walter T.A., Fan S.X., Medchill M.T., Berger C.S., Decker H.J., Sandberg A.A. inv(12)(p11.2q13) in an endometrial polyp. Cancer Genet. Cytogenet. 1989, 41:99-103.
21. Schoenmakers E.F., Kools P.F., Mols R., Kazmierczak B., Bartnitzke S., Bullerdiek J., Dal Cin P., De Jong P.J., Van den Berghe H., Van de Ven W.J. Physical mapping of chromosome 12q breakpoints in lipoma, pleomorphic salivary gland adenoma, uterine leiomyoma, and myxoid liposarcoma. Genomics 1994, 20:210-222.
22. De Martino I., Visone R., Wierinckx A., Palmieri D., Ferraro A., Cappabianca P., Chiappetta G., Forzati F., Lombardi G., Colao A., Trouillas J., Fedele M., Fusco A. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 2009, 69:1844-1850.
23. Kazmierczak B., Wanschura S., Meyer-Bolte K., Caselitz J., Meister P., Bartnitzke S., Van de Ven W., Bullerdiek J. Cytogenic and molecular analysis of an aggressive angiomyxoma. Am. J. Pathol. 1995, 147:580-585.
24. Rahman M.M., Qian Z.R., Wang E.L., Sultana R., Kudo E., Nakasono M., Hayashi T., Kakiuchi S., Sano T. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br. J. Cancer 2009, 100:501-510.
25. Venkatesan N., Kandalam M., Pasricha G., Sumantran V., Manfioletti G., Ono S.J., Reddy M.A., Krishnakumar S. Expression of high mobility group A2 protein in retinoblastoma and its association with clinicopathologic features. J. Pediatr. Hematol. Oncol. 2009, 31:209-214.
26. Huang M.L., Chen C.C., Chang L.C. Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer. Int. J. Colorectal. Dis. 2009, 24:1281-1286.
27. Watanabe S., Ueda Y., Akaboshi S., Hino Y., Sekita Y., Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 2009, 174:854-868.
28. Motoyama K., Inoue H., Nakamura Y., Uetake H., Sugihara K., Mori M. A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin. Cancer Res. 2008, 14:2334-2340.
29. Balcerczak M., Pasz-Walczak G., Balcerczak E., Wojtylak M., Kordek R., Mirowski M. HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging. Pathol. Res. Pract. 2003, 199:641-646.
30. Wang Y.C., Chen Y.L., Yuan R.H., Pan H.W., Yang W.C., Hsu H.C., Jeng Y.M. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis 2010, 31:1516-1522.
31. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
32. Greten T.F., Korangy F., Manns M.P., Malek N.P. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer 2009, 100:19-23.
33. Ocker M., Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 2007, 39:1367-1374.
34. Jana S., Paliwal J. Apoptosis: potential therapeutic targets for new drug discovery. Curr. Med. Chem. 2007, 14:2369-2379.
35. Ellis L., Atadja P.W., Johnstone R.W. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 2009, 8:1409-1420.
36. Ocker M. Deacetylase inhibitors-focus on non-histone targets and effects. World J. Biol. Chem. 2010, 1:55-61.
37. Di Fazio P., Schneider-Stock R., Neureiter D., Okamoto K., Wissniowski T., Gahr S., Quint K., Meissnitzer M., Alinger B., Montalbano R., Sass G., Hohenstein B., Hahn E.G., Ocker M. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol. 2010, 32:285-300.
38. Park C.W., Zeng Y., Zhang X., Subramanian S., Steer C.J. Mature microRNAs identified in highly purified nuclei from HCT116 colon cancer cells. RNA Biol. 2010, 7:606-614.
39. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009, 5:601-612.
40. Di Fazio P., Ocker M., Montalbano R., Drugs New Old fashioned ways: ER stress induced cell death. Curr. Pharm. Biotechnol. 2011.
41. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
42. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
43. Mavrakis K.J., Leslie C.S., Wendel H.G. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle 2011, 10.
44. Tie J., Fan D. Big roles of microRNAs in tumorigenesis and tumor development. Histol. Histopathol. 2011, 26:1353-1361.
45. Qian Z.R., Asa S.L., Siomi H., Siomi M.C., Yoshimoto K., Yamada S., Wang E.L., Rahman M.M., Inoue H., Itakura M., Kudo E., Sano T. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod. Pathol. 2009, 22:431-441.
46. Ashar H.R., Chouinard R.A., Dokur M., Chada K. In vivo modulation of HMGA2 expression. Biochim. Biophys Acta 1799, 2010:55-61.
47. Valeri N., Vannini I., Fanini F., Calore F., Adair B., Fabbri M. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm. Genome 2009, 20:573-580.
48. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006, 66:1277-1281.
49. Feng Z., Zhang C., Wu R., Hu W. Tumor suppressor p53 meets microRNAs. J. Mol. Cell. Biol. 2011, 3:44-50.
50. Boominathan L. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One 2010, 5:e10615.
51. Jakymiw A., Patel R.S., Deming N., Bhattacharyya I., Shah P., Lamont R.J., Stewart C.M., Cohen D.M., Chan E.K. Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 2010, 49:549-559.
52. Suzuki H.I., Miyazono K. Emerging complexity of microRNA generation cascades. J. Biochem. 2011, 149:15-25.
53. Newman M.A., Hammond S.M. Emerging paradigms of regulated microRNA processing. Genes Dev. 2010, 24:1086-1092.
54. Newman M.A., Thomson J.M., Hammond S.M. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 2008, 14:1539-1549.
55. Thomas M., Lieberman J., Lal A. Desperately seeking microRNA targets. Nat. Struct. Mol. Biol. 2010, 17:1169-1174.
56. Helland A., Anglesio M.S., George J., Cowin P.A., Johnstone C.N., House C.M., Sheppard K.E., Etemadmoghadam D., Melnyk N., Rustgi A.K., Phillips W.A., Johnsen H., Holm R., Kristensen G.B., Birrer M.J., Pearson R.B., Borresen-Dale A.L., Huntsman D.G., deFazio A., Creighton C.J., Smyth G.K., Bowtell D.D. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011, 6:e18064.
57. Lee S., Jung J.W., Park S.B., Roh K., Lee S.Y., Kim J.H., Kang S.K., Kang K.S. Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell. Mol. Life Sci. 2011, 68:325-336.
58. Romanov V.S., Abramova M.V., Svetlikova S.B., Bykova T.V., Zubova S.G., Aksenov N.D., Fornace A.J., Pospelova T.V., Pospelov V.A. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle 2010, 9:3945-3955.
59. Fedele M., Pierantoni G.M., Visone R., Fusco A. Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006, 5:2045-2048.
60. Fedele M., Pierantoni G.M., Visone R., Fusco A. E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div. 2006, 1:17.
61. Fedele M., Visone R., De Martino I., Troncone G., Palmieri D., Battista S., Ciarmiello A., Pallante P., Arra C., Melillo R.M., Helin K., Croce C.M., Fusco A. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006, 9:459-471.
62. Cattaruzzi G., Altamura S., Tessari M.A., Rustighi A., Giancotti V., Pucillo C., Manfioletti G. The second AT-hook of the architectural transcription factor HMGA2 is determinant for nuclear localization and function. Nucleic Acids Res. 2007, 35:1751-1760.